CLINICAL STUDY

Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study

Mario Salvi, Giua Vannucchi, Irene Campi, Nicola Currò, Davide Dazzi, Simona Simonetta, Paola Bonara, Stefania Rossi, Clara Sina, Claudio Guastella, Roberto Ratiglia and Paolo Beck-Peccoz

Departments of Medical Sciences, Ophthalmology, Radiology, Otolaryngology and Internal Medicine, University of Milan, Fondazione Ospedale Maggiore IRCCS, Milan, Italy, Pathology Unit, Department of Medicine, Surgery and Dentistry, Ospedale San Paolo, Milan and Division of Internal Medicine, Ospedale di Fidenza, Parma, Italy

(Correspondence should be addressed to P Beck-Peccoz: Email: paolo.beckpeccoz@unimi.it)

Abstract

Introduction: Hyperthyroid Graves’ disease (GD) is a B-cell-mediated condition caused by TSH receptor antibodies (TRAb), which decline when GD remits. Anti-CD20 monoclonal antibody rituximab (RTX) induces transient B-cell depletion that may potentially modify the active inflammatory phase of thyroid-associated ophthalmopathy (TAO).

Methods: Nine patients with GD, seven with active TAO, two with mild lid signs, were studied. The trial was only approved as an open pilot study; thus we compared the effect of RTX therapy to that of i.v. glucocorticoids (IVGC) in 20 consecutive patients. Patients were treated with RTX (1000 mg i.v. twice at 2-week interval) or with IVGC (500 mg i.v. for 16 weeks). TAO was assessed by the clinical activity score (CAS) and severity was classified using NOSPECS (No signs or symptoms; Only signs (lid); Soft tissue involvement; Proptosis, Extraocular muscle involvement; Corneal involvement; Sight loss). Thyroid function and lymphocyte count were measured by standardized methods.

Results: All patients attained peripheral B-cell depletion with the first RTX infusion. Minor side effects were reported in three patients. Thyroid function was not affected by RTX therapy and hyperthyroid patients required therapy with methimazole. After RTX, the changes in the levels of thyroglobulin antibodies, thyroperoxidase antibodies and TRAb were neither significant nor correlated with CD20 depletion (P NS). CAS values before RTX were 4.7 ± 0.5 and decreased to 1.8 ± 0.8 at the end of follow-up (P < 0.0001) and more significantly compared with IVGC (P < 0.05). Proptosis decreased significantly after RTX both in patients with active TAO (ANOVA; P < 0.0001) and those with lid signs (ANOVA; P < 0.003). The degree of inflammation (class 2) decreased significantly in response to RTX (ANOVA; P < 0.001). Relapse of active TAO was not observed in patients treated with RTX, but occurred in 10% of those treated with IVGC, who also experienced adverse effects more frequently (45 vs 33% of patients).

Conclusions: RTX positively affects the clinical course of TAO, independently of either thyroid function or circulating antithyroid antibodies, including TRAb. If our findings are confirmed in large controlled studies, RTX may represent a useful therapeutic tool in patients with active TAO.

European Journal of Endocrinology 156 33–40

Introduction

Hyperthyroidism in Graves’ disease (GD) is based on a B-cell driven mechanism leading to sustained production of immunoglobulins G stimulating the thyroid stimulating hormone (TSH) receptor on the thyrocytes (1, 2). This phenomenon emerges in the context of an autoimmune thyroiditis characterized by typical lymphocytic infiltration of the thyroid tissue (3). Serum TSH receptor antibodies (TRAb) correlate well with the clinical course of hyperthyroidism and typically decline when GD is remitting (4). To date, thyroid-associated ophthalmopathy (TAO) does not have a known pathogenesis. It is known that both Th1 and Th2 cytokine patterns are involved and that the TSH receptor is expressed on orbital preadipogenic fibroblasts and may be a target for immunoglobulin G-stimulated hyperproduction of adipose tissue (5, 6). There is no evidence of pathogenic autoantibodies, TRAb (7) and eye muscle-directed antibodies (8) occurring only at a second pathogenetic step or epiphenomena. Elevated serum TRAb levels have been correlated to the active phase of TAO (9), but this may not imply a role in the disease pathogenesis, since their
titers have been shown not to vary in relation to the stabilization (10–12) and the duration of the clinical features (M Salvi et al. unpublished observations).

Rituximab (RTX) is a humanized chimeric anti-CD20 MAB whose variable (antigen-binding) region is derived from a mouse antibody. The binding of RTX to CD20 antigen blocks the activation and differentiation of B cells, since CD20 protein is expressed on the surface of pre-B and mature B lymphocytes, but not on stem cells, pro-B lymphocytes, and plasma cells (13, 14). Therefore, treatment with RTX leads to specific elimination of B cells without affecting the regeneration of B cells from stem cells and the production of immunoglobulins by plasma cells.

The rationale of the present study is based on the potential effect of RTX treatment on B-cell-mediated immunity in GD and TAO (15, 16). When compared with the natural course of Graves’ hyperthyroidism, TAO has a self-limiting evolution with an active phase lasting a relatively limited time (6–18 months) and followed by clinical stabilization. We thought that transient B-cell depletion induced by RTX, which generally lasts 4–6 months, may effectively modify the active inflammatory phase of TAO and its subsequent clinical course.

Here, we report the results of an open study on the treatment with RTX of nine patients with GD and ophthalmopathy. All patients showed a clear clinical improvement of TAO shortly after RTX infusion, but not of hyperthyroidism, with persistence of elevated serum TRAb titers, in spite of peripheral B-cells depletion.

**Patients and methods**

**Patients**

We have studied nine patients with GD, seven women and two men, aged 31–51 year (mean ± s.e.m. age 44.8 ± 2.1), of whom seven had active TAO and two, with newly diagnosed hyperthyroidism, only mild lid signs. Five patients were smokers, two were ex-smokers and two never smoked. At the time of RTX therapy, four patients were hyperthyroid and untreated; five were euthyroid, two on methimazole (MMI), two in remission after a previous course of MMI, and one patient on L-thyroxine for 12 months after previous thyroidectomy (Table 1). TAO was diagnosed as moderate–severe with CAS of three or greater in six patients, and severe in one patient with CAS of seven and rapid deterioration of visual field and of visual acuity. In two of these patients, clinically active TAO had relapsed 3 and 4 months respectively after previous steroid therapy. Two patients had only lid signs and mild conjunctival inflammation and were treated to test the effect of RTX on Graves’ hyperthyroidism. After RTX, eight patients have been studied up to 12 months and one up to 5 months respectively of the follow-up period. Five TAO patients have been studied at 18 months after RTX.

Since we could not carry out a randomized controlled therapeutic trial, as the drug manufacturer only allowed a pilot open study, we decided to compare the effect of RTX therapy with that of i.v. glucocorticoids (IVGC) in a group of 20 consecutive patients, 17 women and three men, aged 30–82 years (mean ± s.e.m. age 55.4 ± 2.9 years), treated according to the standard protocol applied in our center. Twelve patients were smokers, four ex-smokers, and four never smoked. Of these patients, 19 had GD and were euthyroid, 16 on antithyroid therapy, two because of disease remission, and one on L-T4 after thyroidectomy. One patient had euthyroid Graves’ ophthalmopathy. All patients had active TAO; three had mild, 13 had moderate, and four had severe disease. All patients were treated with 500 mg of methylprednisolone once a week for 16 weeks and were studied up to 12 months after therapy. IVGC therapy was discontinued at 10 weeks in one patient who

**Table 1 Clinical parameters of patients with thyroid-associated ophthalmopathy treated with rituximab.**

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex</th>
<th>Age</th>
<th>Smoking</th>
<th>Thyroid status</th>
<th>Thyroid volume (ml)</th>
<th>Therapy</th>
<th>TAO activity (CAS)</th>
<th>TAO severity (NOSPECS)</th>
<th>Orbital involvement</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F</td>
<td>31</td>
<td>No</td>
<td>Hyperthyroid</td>
<td>19.5</td>
<td>Propranolol 120 mg</td>
<td>2</td>
<td>2a3040</td>
<td>Fat hypertrophy</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>51</td>
<td>No</td>
<td>Hyperthyroid</td>
<td>17.6</td>
<td>Methimazole 10 mg</td>
<td>5</td>
<td>2b3a4b</td>
<td>Normal</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>46</td>
<td>Yes</td>
<td>Euthyroid</td>
<td>17.6</td>
<td>–</td>
<td>–</td>
<td>2b3a4b</td>
<td>OD: MR, OS, IR</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>47</td>
<td>No</td>
<td>Euthyroid</td>
<td>7.2</td>
<td>–</td>
<td>5</td>
<td>2a3a4b</td>
<td>Fat hypertrophy</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>40</td>
<td>Yes</td>
<td>Hyperthyroid</td>
<td>68.4</td>
<td>–</td>
<td>5</td>
<td>2a304a</td>
<td>OD: MR, IR (OD &gt; OS)</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>49</td>
<td>No</td>
<td>Hyperthyroid</td>
<td>14.2</td>
<td>–</td>
<td>3</td>
<td>2a3a40</td>
<td>OD: SR, SR</td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>50</td>
<td>Yes</td>
<td>Euthyroid</td>
<td>11.5</td>
<td>L-T4 125 mcg</td>
<td>7</td>
<td>2c304b</td>
<td>Fat hypertrophy</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>43</td>
<td>Yes</td>
<td>Euthyroid</td>
<td>13.8</td>
<td>Methimazole 2.5 mg</td>
<td>6</td>
<td>2c3b4b</td>
<td>OD: all muscles</td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>54</td>
<td>Yes</td>
<td>Euthyroid</td>
<td>13.8</td>
<td>Methimazole 2.5 mg</td>
<td>6</td>
<td>2c3b4b</td>
<td>Initial apical crowding</td>
</tr>
</tbody>
</table>

OD, OS: right, left eye; MR, medial rectus; IR, inferior rectus; SR, superior rectus; LR, lateral rectus; CAS, clinical activity score; NOSPECS, severity according to Werner SC, 1969.
had acute optic neuropathy and underwent orbital decompression.

Patients were seen in our joint thyroid–eye clinic and at each visit blood was taken for thyroid function tests, serum autoantibody testing, and, in the RTX group, for the study of peripheral lymphocytes. Patients treated with RTX were studied at 4, 8, 12, 16, 20, 30, 50, and 70–75 weeks, while those treated with IVGC were studied at 8, 20, 30, and 50 weeks after the first drug infusion (Fig. 1). Based on clinical findings, thyroid ultrasound was also carried out in RTX treated patients to assess goiter changes. The ophthalmological examination included lid fissure and Hertel measurements, color vision, cover test, Hess–Lancaster screen, visual acuity, tonometry, fundus examination, and visual field. Orbital computed tomography (CT) scan was performed in all patients to study the intraorbital tissue components. At the second ophthalmological visit and at each subsequent examination the CAS was calculated (17) in order to monitor the clinical improvement of the

patients. The severity was classified according to the NOSPECS score (18).

**Therapeutic protocol**

Patients were submitted to treatment with RTX, a chimeric human–mouse MAB (MabThera) kindly provided by Hoffman La Roche, Basel, Switzerland. The study protocol was approved by the ethics committee of the hospital and the patient gave informed consent for the therapy. The recommended therapeutic protocol was the one used for treatment of patients with rheumatoid arthritis and consisted of i.v. infusion of 1000 mg of RTX over approximately 4 h and 15 min, twice at a 2-week interval. One hour prior to RTX infusion, we administered paracetamol (1 g) and chlorphenamine (10 mg) orally to prevent possible allergic reactions. Patients treated with IVGC underwent 16 weekly infusions of 500 mg/week of methylprednisolone, the last 2 cycles 250 mg/week (Fig. 1).

---

**Figure 1** Modalities of rituximab and methylprednisolone administration in patients with active thyroid-associated ophthalmopathy and prevalence of the adverse reactions to treatments.  ● Biochemical and ophthalmological assessment; ○ biochemical assessment; † i.v. administration.
Biochemical and immunological testing

Serum TSH and FT4 concentrations and antithyroglobulin antibodies (TgAb), and antithyroperoxidase antibodies (TPOAb) were measured using the AutoDELFIA technique (Perkin–Elmer-Life Sciences, Wallac Oy, Turku, Finland). Serum TSH receptor antibodies (TRAb), detected as TSH binding inhibitory immunoglobulins, were measured using a 2nd generation TRAK human lumitest (B R A H M S, AG, Henningsdorf/Berlin, Germany).

Cytofluorimetric analysis

In patients treated with RTX, we looked at the pattern of peripheral blood lymphocytes before therapy and throughout the study period. Moreover, in one patient, we had the opportunity to analyze the lymphocytes subpopulations within the thyroid tissue, at thyroidectomy, in a lymph node of the neck, removed during surgery, and within the orbital fat and connective tissue, at decompression (15). We have studied the standard immunophenotypic panel (CD3+, CD3+4+, CD3+8+, CD3+DR+, CD20+, CD19+5+, CD5+16+3) on aliquots of around 10⁵ lymphocytes, submitted to standard triple staining procedures in order to carry out immunogating with CD45, and we analyzed pairs of monoclonal antibodies to subpopulations of T, B, and NK cells, then processed in the flowcytometer (BD Facsana, Cell-quest software, Becton-Dickinson, San José, CA, USA).

Statistical analysis

The changes of serum antibody levels and of CAS and proptosis values in response to RTX therapy and by comparison with IVGC treatment were analyzed by repeated measures ANOVA. NOSPECS class 2 and motility scores were tested by Wilcoxon. Correlations were analyzed by non-parametric Spearman’s rank test.

Results

Effects of RTX: B-cell depletion and adverse reactions

All patients attained peripheral B-cell depletion with the first RTX infusion (Fig. 2). In all nine patients, the decrease of peripheral CD20+ count in response to RTX was significant (ANOVA; P<0.0001). One patient showed no CD20+ lymphocytes after the first RTX infusion but persistence of 2.8–4.9% CD 19+ lymphocytes throughout the study period. Peripheral B-cell depletion lasted 5 months in five patients and 4 months in three patients, while one patient is still B-cell depleted at 5 months of follow-up. All patients well tolerated RTX and only minor side effects were reported in three patients during the first infusion (Fig. 1).

Effects of RTX on thyroid function

Thyroid function was not affected by RTX therapy. The two patients with GD and only lid signs did not show
improvement of hyperthyroidism during RTX-induced B-cell depletion. One of them was subclinically hyperthyroid and eventually became euthyroid at 8 months after RTX. Among TAO patients, the two, who were euthyroid because of disease remission before RTX, remained so without requiring therapy throughout the study period. In the three patients with untreated disease, hyperthyroidism did not improve and therefore MMI was started at 6–12 weeks during RTX-induced B-cell depletion. One patient on MMI, in whom the drug was stopped because of elevation of serum TSH suggestive for disease remission, rapidly showed a relapse of hyperthyroidism, while persisting peripheral B-cell depletion.

**Effects of RTX on thyroid autoimmunity**

After RTX, the changes of levels of TgAb, TPOAb, and TRAb were not significant (ANOVA; \( P = \text{NS} \)) and were not correlated to CD20+ lymphocytes depletion (Spearman; \( P = \text{NS} \); Fig. 2). Mean (±S.E.M.) serum TgAb levels were 52 ± 24.6 U/L before therapy and 13.4 ± 4.6 U/L at the end of the follow-up period and their decrease showed a slightly significant negative correlation with time (Spearman; \( R = -0.27, P < 0.04 \)), likely to be related to the attainment of euthyroidism after antithyroid treatment. Serum TPOAb were detectable in five out of the nine patients and their titters slightly increased in two at 2–4 weeks of treatment. Serum TRAb levels were 19.3 ± 6.7 U/L before treatment and 11.5 ± 9.2 U/L 30 weeks after RTX (ANOVA; \( P = \text{NS} \)) (Table 2) and their changes did not correlate with either the phase of depletion or of return of CD20 lymphocytes in the periphery (Spearman; \( P = \text{NS} \)). Serum TRAb levels did not even decrease in the patient on l-thyroxine who underwent total thyroidectomy a year before. Serum TRAb levels decreased further at 75 weeks of follow-up with a slightly significant negative correlation with time (Spearman; \( R = -0.33, P < 0.01 \)), when all patients reached stable euthyroidism. In fact two patients, one euthyroid and one hyperthyroid not treated with MMI, who had slightly increased basal serum TRAb levels (< 5 U/L), after RTX therapy showed progressive normalization of serum TRAb levels in relation to remission of Graves’ hyperthyroidism. In the patient who relapsed shortly after discontinuation of MMI, while still having B-cell depletion, serum TRAb levels showed a sudden rise preceding hyperthyroidism, as commonly observed in GD patients.

**Effect of RTX on clinical TAO**

In all the patients treated with RTX, we have observed a definite clinical improvement of TAO, including the one at 5 months of the follow-up period. Data were statistically analyzed at 30 weeks of follow-up and are shown in Table 3. The mean (±S.E.M.) CAS value before therapy was 4.7 ± 0.5 and decreased to 1.8 ± 0.8 (ANOVA; \( P < 0.0001 \)). A decrease of CAS to < 3 was consistently observed within a month of treatment with RTX. We also studied the effect of RTX therapy on disease severity by separating out the changes of parameters like soft tissue inflammation (NOSPECS, class 2), proptosis (NOSPECS, class 3), and motility involvement (NOSPECS, Class 4). Proptosis decreased significantly after RTX in both patients with active TAO (ANOVA; \( P < 0.0001 \)) and in those with GD and lid signs (ANOVA; \( P < 0.003 \)). The degree of inflammation (class 2) decreased significantly in response to RTX (ANOVA; \( P < 0.001 \)) as well as the degree of motility impairment (Wilcoxon; \( P < 0.05 \)), as also shown by the Gorman score in Table 4 (19). Interestingly, the clinical picture has progressively stabilized after treatment and we have not observed relapse of active TAO in any of the patients both at the time of B-cell return into the peripheral blood, generally at 5–6 months after RTX treatment, and in the subsequent 5–7 months of follow-up, in those who have completed it.

**Comparison of the effects of RTX and IVGC in TAO patients**

Mean (±S.E.M.) serum TRAb levels before IVGC were 16.3 ± 4.9 and 9.3 ± 3.6 U/L after therapy (ANOVA; \( P = \text{NS} \)) (Table 2). The changes were not different compared with RTX therapy (ANOVA; \( P = \text{NS} \)) at 30 weeks.

In the group of 20 TAO patients treated with IVGC, mean (±S.E.M.) CAS value significantly decreased from 4.1 ± 0.3 before to 2.0 ± 0.4 at 30 weeks after therapy (ANOVA; \( P < 0.0001 \)). When compared with the group of TAO (Table 3) patients treated with RTX, we found a significant difference (ANOVA; \( P < 0.05 \)). Patients after

**Table 2** Mean serum TRAb levels (U/L) at baseline and after therapy in patients treated with rituximab or i.v. methylprednisolone.

<table>
<thead>
<tr>
<th>Weeks from therapy</th>
<th>Rituximab therapy (no. 7)</th>
<th>ANOVA</th>
<th>Methylprednisolone therapy (no. 20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>19.3 ± 6.7*</td>
<td></td>
<td>16.3 ± 4.6</td>
</tr>
<tr>
<td>8</td>
<td>18.5 ± 9.3</td>
<td></td>
<td>11.4 ± 4.2</td>
</tr>
<tr>
<td>20</td>
<td>14.8 ± 7.0</td>
<td></td>
<td>8.9 ± 4.1</td>
</tr>
<tr>
<td>30</td>
<td>11.5 ± 9.2</td>
<td></td>
<td>9.3 ± 5.6</td>
</tr>
<tr>
<td>ANOVA</td>
<td>( P = \text{NS} )</td>
<td></td>
<td>Rituximab vs methylprednisolone ( P = \text{NS} )</td>
</tr>
</tbody>
</table>

*Mean ± S.E.M.*
IVGC usually reported amelioration of symptoms and were assessed to have a reduction of the CAS at 6–8 weeks, relatively later compared to RTX. Proptosis significantly improved after IVGC (ANOVA; *P* < 0.003 vs TAO; *P* = 0.3 vs Methylpred), and not differently from RTX therapy (ANOVA; *P* = NS). The degree of Class 2 signs also decreased significantly after IVGC (Wilcoxon; *P* < 0.01). These results did not differ from those observed after RTX (ANOVA; *P* = NS).

Adverse effects were more frequent after IVGC (45 vs 33% of patients) and of greater clinical relevance (Fig. 1). While all the patients responded to RTX (100%), as shown by the significant decrease in the CAS, NOSPECS class 2 and proptosis values, four of the patients did not respond to IVGC and one underwent acute orbital decompression for optic neuropathy, therefore making up to a total of 75% of patients responders. Furthermore, an additional two patients (10%) showed relapse of active TAO at 6–8 weeks after IVGC withdrawal.

### Discussion

This is the first pilot open study on the use of RTX for the treatment of active TAO. The use of RTX in GD and TAO was approved by the scientific board of the drug manufacturing company only as a phase 3 pilot open study. For this reason we were only able to study, as controls, a group of consecutive patients treated with IVGC for active TAO. This allowed us to validate the data on the therapeutic effect of RTX by comparison with what is considered the standard therapy for this disease (20–22). The main finding is that RTX does positively affect the clinical course of TAO, independently of either the thyroid function or the pattern of circulating antithyroid antibodies and in particular of the TRAb.

Response to therapy correlated well with peripheral CD20+ depletion, which was attained in all patients already with the first RTX dose. One patient showed no CD20+ cells after RTX treatment, but persistence of about 3–5% CD 19+ cells, of which about 90% were co-expressing CD 19+5+, characteristic of clones committed to production of autoantibodies (23). We have also previously observed an increased prevalence of CD 19+5+ (about 50%) in the intrathyroidal lymphocytes of the patient who underwent thyroidectomy at the time of initial peripheral B-cell return, 5 months after RTX treatment (15). This lymphocyte subset represents the bulk of cells that reconstitute peripheral blood during the early repletion period (24). Data from RTX therapy studies conducted in human systemic lupus erythematosus show that complete B-cell depletion (arbitrarily defined as depletion to <1% of the total peripheral blood cells) is not necessary for clinical response (25).

Interestingly, B-cell depletion did not cause changes in circulating serum thyroid autoantibodies. This might be due to persistence of plasma cells, which do not express CD20 and may continue to produce antibodies (13, 14), although they would only be measured in the circulation for as long as 4–6 weeks, if one considers that the half life of human IgG is approximately 3 weeks (26). Our data rather suggest that autoantibodies may not be produced by peripheral B lymphocytes, but perhaps by lymphocytes in the thyroid or in other

### Table 3 Comparison between rituximab and i.v. methylprednisolone therapy in patients with Graves’ disease (GD) and associated ophthalmopathy (TAO).

<table>
<thead>
<tr>
<th>Patients (no.)/therapy</th>
<th>Weeks</th>
<th>Proptosis</th>
<th>P (ANOVA)</th>
<th>CAS</th>
<th>P (ANOVA)</th>
<th>Class 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>GD (no. 2)/rituximab</td>
<td>0</td>
<td>19.0 ± 0.7</td>
<td><em>NS</em></td>
<td></td>
<td><em>NS</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>18.0 ± 1.2</td>
<td>NS</td>
<td></td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>17.7 ± 1.1</td>
<td>NS</td>
<td></td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>30</td>
<td>17.3 ± 0.9</td>
<td><em>NS</em></td>
<td></td>
<td><em>NS</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>P</em> &lt; 0.003 vs TAO</td>
<td><em>P</em> &lt; 0.015</td>
<td></td>
<td><em>P</em> &lt; 0.0001 vs Methylpred.</td>
<td><em>P</em> &lt; 0.01</td>
</tr>
<tr>
<td>TAO (no. 7)/rituximab</td>
<td>0</td>
<td>22.4 ± 0.5</td>
<td>NS</td>
<td></td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>21.8 ± 0.6</td>
<td>NS</td>
<td></td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>21.3 ± 0.6</td>
<td>NS</td>
<td></td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>30</td>
<td>20.9 ± 0.6</td>
<td>NS</td>
<td></td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>P</em> &lt; 0.0001</td>
<td><em>P</em> &lt; 0.001</td>
<td></td>
<td><em>P</em> &lt; 0.0001</td>
<td><em>P</em> &lt; 0.0001</td>
</tr>
<tr>
<td>TAO (no. 20)/methylpred.</td>
<td>0</td>
<td>22.6 ± 0.6</td>
<td>NS</td>
<td></td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>22.3 ± 0.6</td>
<td>NS</td>
<td></td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>21.9 ± 0.6</td>
<td>NS</td>
<td></td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>30</td>
<td>22.1 ± 0.6</td>
<td>NS</td>
<td></td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>P</em> &lt; 0.014 vs Rituximab</td>
<td><em>P</em> &lt; 0.0001</td>
<td></td>
<td><em>P</em> &lt; 0.0001 vs Rituximab</td>
<td><em>P</em> &lt; 0.0001</td>
</tr>
</tbody>
</table>

*Mean ± S.E.M.*
lymphoid organs such as the bone marrow or the spleen (27). Persistence of small germinal centers was in fact shown in thyroid surgical specimens from thyroidectomy of one of our patients carried out at the time of initial B-cell return (15).

Discrepancies between a positive clinical response and an effect on circulating autoantibodies after RTX have been observed in systemic autoimmune diseases such as lupus (28) and rheumatoid arthritis (29). In our study, the findings argue against a pathogenic role of TRAb in TAO (30). Serum TRAb levels declined in relation to time only when disease remission occurred, spontaneously in one patient and as a consequence of MMI therapy in the others (11, 31). The fact that RTX treatment had no effect on hyperthyroidism in GD patients is probably consequent to its absent effect on TRAb production. Throughout the B-cell depletion period we needed to either commence or maintain treatment with MMI, which was administered by a standard dose titration protocol until stable euthyroidism in five of our hyperthyroid patients.

Progression to euthyroidism without therapy was observed only in one patient who had relatively low serum TRAb titers at the time of RTX therapy. Although our findings were not derived from a preliminary and not controlled study, we believe that the observed improvement of active TAO after RTX therapy is not due to spontaneous variations of the natural course of the disease for three reasons. First, the decrease of the NOSPECS and the CAS scores are evident within 4–6 weeks from RTX therapy, earlier than the average response time observed after steroids in the patients of the group of controls. Second, two of the patients were treated successfully with RTX after having not responded to IVGC and presenting a relapse of TAO after steroid withdrawal (15, 36). Third, none of the nine patients has shown relapse of eye inflammation after RTX, despite the fact that the drug had no effect on hyperthyroidism and TRAb.

In conclusion, if our findings are confirmed in larger and controlled studies, we believe that RTX may represent a useful therapeutic tool in patients with active TAO and may be more effective than the standard therapy with IVGC. Besides being safe, RTX is better tolerated by patients who also seem to prefer its therapeutic protocol, such as the one applied in this study.

Acknowledgements

We wish to thank Dr Martino Introna of the Division of Haematology, Ospedali Riuniti, Bergamo, Italy for fruitful discussion on the rationale of the work and Dr Tim Shaw of Hoffman La Roche, England for providing us with Mab Thera. This work is supported in part by MURST, Roma and by Fondazione Ospedale Policlinico, IRCCS, Milano, Italy.

References


www.eje-online.org


6 Valyasevi RW, Harteneck DA, Dutton CM & Bahn RS. Stimulation of adiopogenesis, peroxisome proliferator-activated receptor-gamma (PPARgamma), and thyrotropin receptor by PPARgamma agonist in human preadipocytic fibroblasts. *Journal of Clinical Endocrinology and Metabolism* 2002 87 2352–2358.


19 Gorman CA. The measurement of change in Graves' ophthalmopathy. *Thyroid* 1998 8 539–543.


30 Drezhuga HA. Are there more than antibodies to the thyroid? *Arthritis and Rheumatism* 2006 90 252–259.


35 Rodriguez-Pinto D. B cells as antigen presenting cells. *Cellular Immunology* 2005 238 67–75.